Three-year Hematology purchasing agreement

About this update from Ekf Diagnostics Holdings Plc

  EKF Diagnostics Holdings plc ("EKF" or the "Company")   Three-year Hematology purchasing agreement with Blood Centers of America   EKF Diagnostics Holdings plc  (AIM: EKF), the AIM-quoted global diagnostics business, announces that it has signed a three year Group purchasing agreement with Blood Centers of America Inc ("BCA"), the largest blood supply network in the U.S. and uniquely positioned to sustain, advocate and mobilize for the nation's blood supply. BCA's membership consist of more than 60 independent community blood centers, which collect and distribute 50% of the nation's blood supply. For more information: https://bca.coop/   This new agreement provides pricing for the DiaSpect Tm Hand-held hemaglobin analyzer and associated consumable cuvettes. Pricing is also provided for an EKF Link IT License, which enables a paperless workflow and streamlined quality control management, allowing operators to focus on the patients and donors they serve instead of the analyzer in use. EKF Link enables new functions like Hematocrit calculation, quality control management, and patient data management. EKF will also provide dedicated product training, including support with product evaluations as well as validation and verification activities to fully integrate the DiaSpect Tm offering.   Commenting, Sam Keith, SVP of Supply Chain, said : " BCA are pleased to be partnering with EKF on a master supply agreement following on from the high interest EKF generated at the Association for the Advancement of Blood & Biotherapies Annual Meeting in San Diego in October 2025. The Company presented a poster demonstrating the exceptional efficacy of the DiaSpect Tm product, especially when combined with the EKF Link connectivity solution. "   The poster is available to view here: http://ekfdiagnostics.com/events/aabb-2025/poster   Commenting, Gavin Jones, Chief Executive Officer, said: "We are very pleased with the early successes we are seeing as we implement our five-year strategic development plan. In that, we identified Hemoglobin testing as the most significant growth opportunity within our Point-of-Care (POC) portfolio and we remain steadfast in our ambition to become number 1 in global POC Hematology testing. The agreement with BCA is a significant milestone in this ambition, with the US blood bank market considered to be one of the largest addressable markets in the world."   The person responsible for arranging the release of this Announcement on behalf of the Company is Gavin Jones, Chief Executive Officer.   EKF Diagnostics Holdings plc www.ekfdiagnostics.com Julian Baines, Executive Chair  via Walbrook PR Gavin Jones, Chief Executive Officer   Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000 Phil Davies / Patrick Weaver Walbrook PR Limited Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654       About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )   EKF is an AIM-listed global diagnostics business focussed on:   ● Point-of-Care  analysers in the key areas of Hematology and Diabetes  ● Life Sciences  services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.   EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.  

View stock analysis, news, and events for Ekf Diagnostics Holdings Plc